The U.S. Food and Drug Administration has approved Otarmeni, the first-ever dual adeno-associated virus (AAV) vector-based gene therapy, to treat genetic hearing loss. This landmark decision marks a significant breakthrough in utilizing advanced viral vector technology to address hereditary medical conditions.